Insight on Oncology in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

Type Product title / description Pub Price
Report
Report

Myelodysplastic Syndrome: An Underserved Population Offers Commercial Opportunity

SuperGen/MGI Pharma's Dacogen and Celgene's Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However, a significant proportion of the MDS population will be left underserved by pharmacotherapy.

Published By Datamonitor
18 Oct 2005 $1900
Buy
Report
Report

Stakeholder Insight: Gastric Cancer

Explores key issues in the gastric cancer market, including diagnosis and treatment patterns, specific drug regimens used at each line of therapy, key prescribing influences and predicted performance of late-phase pipeline products.

Published By Datamonitor
15 Sep 2010 $15200
Buy
Report
Report

Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Herceptin dominates the HER-2-positive market

Primary research-based analysis of the hormone receptor-positive breast cancer market. Includes epidemiology, patient segmentation, treatment trends, and future treatment scenarios. Separate coverage of triple-negative and HER-2-positive subsets.

Published By Datamonitor
03 Nov 2010 $6400
Buy
Report
Report

Stakeholder Opinions: Hepatocellular cancer

Stakeholder Opinions: Hepatocellular Cancer discusses issues in the treatment of hepatocellular cancer, highlighting potential target populations for drug developers, treatment limitations and unmet needs, and an overview of the current pipeline.

Published By Datamonitor
01 Dec 2010 $2800
Buy
Report
Report

Pipeline Insight: Lung Cancers Overview – Intensive R&D activity but little improvement in patient outcomes

Overview of the current lung cancers clinical pipeline, including in-depth analysis of late-phase products, clinical trial data, sales forecasts through to 2019, Datamonitor drug assessment summaries and key opinion leader insight.

Published By Datamonitor
10 Dec 2010 $3600
Buy
Report
Report

Pipeline Insight: Cancer Overview Malignant Melanoma, Neuroendocrine Tumors and Thyroid Cancer - New drug approvals likely after decades of little progress

Overview of the current melanoma, thyroid cancer and neuroendocrine tumor pipelines, including in-depth analysis of late-phase products, sales forecasts through to 2019, Datamonitor drug assessment summaries and key opinion leader insight.

Published By Datamonitor
10 Dec 2010 $3600
Buy
Report
Report

Epidemiology: Hepatocellular Cancer - Hepatocellular cancer is a common cancer worldwide and incidence is increasing in the US and Europe

Overview of hepatocellular cancer definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets.

Published By Datamonitor
12 Dec 2010 $2800
Buy
Report
Report

Epidemiology: Gastric Cancer - Gastric cancer is the fourth most common cancer in the seven major markets and the number of incident cases will continue to decline throughout the forecast period

Overview of gastric cancer definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets.

Published By Datamonitor
13 Dec 2010 $2800
Buy
Report
Report

Epidemiology: Breast Cancer - The most common cancer in women worldwide, and both incidence and prevalence are increasing

Overview of breast cancer definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets.

Published By Datamonitor
17 Dec 2010 $2800
Buy
Report
Report

Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients

Overview of the current breast and ovarian cancer pipelines, including in-depth analysis of late-phase products, sales forecasts through to 2019, Datamonitor drug assessment summaries and key opinion leader insight.

Published By Datamonitor
31 Jan 2011 $3600
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

No help is available.